These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 19239360)

  • 1. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    Archin NM; Espeseth A; Parker D; Cheema M; Hazuda D; Margolis DM
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):207-12. PubMed ID: 19239360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    Archin NM; Keedy KS; Espeseth A; Dang H; Hazuda DJ; Margolis DM
    AIDS; 2009 Sep; 23(14):1799-806. PubMed ID: 19590405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir.
    Ling L; Kim M; Soper A; Kovarova M; Spagnuolo RA; Begum N; Kirchherr J; Archin N; Battaglia D; Cleveland D; Wahl A; Margolis DM; Browne EP; Garcia JV
    mBio; 2024 Sep; 15(9):e0163224. PubMed ID: 39136440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.
    Ramakrishnan R; Liu H; Rice AP
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):137-41. PubMed ID: 24528253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
    Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
    J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
    Shan L; Xing S; Yang HC; Zhang H; Margolick JB; Siliciano RF
    J Antimicrob Chemother; 2014 Jan; 69(1):28-33. PubMed ID: 23999005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
    Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
    J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.
    Edelstein LC; Micheva-Viteva S; Phelan BD; Dougherty JP
    AIDS Res Hum Retroviruses; 2009 Sep; 25(9):883-7. PubMed ID: 19689202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
    Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
    PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.
    Reardon B; Beliakova-Bethell N; Spina CA; Singhania A; Margolis DM; Richman DR; Woelk CH
    AIDS; 2015 Nov; 29(17):2235-44. PubMed ID: 26258524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
    Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
    J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression.
    Ylisastigui L; Archin NM; Lehrman G; Bosch RJ; Margolis DM
    AIDS; 2004 May; 18(8):1101-8. PubMed ID: 15166525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.